$RGEN (Repligen Corporation)

$RGEN {{ '2016-05-19T13:51:29+0000' | timeago}} • Announcement

$RGEN said it anticipates the proceeds from the offering to be about $100MM, excluding any exercise of underwriters' option to buy additional $15MM of Notes. The company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

$RGEN {{ '2017-06-23T12:45:15+0000' | timeago}} • Announcement

$RGEN entered into a definitive merger agreement with privately-held Spectrum, Inc. for about $359MM, comprised of $120MM in cash and 6.2MM shares of Repligen stock. The transaction is expected to be completed during 3Q17.

$SGEN {{ '2017-06-15T12:21:22+0000' | timeago}} • Announcement

Pharma firms $SGEN and $BMY presented an interim analysis from the phase 1/2 clinical trial of  lymphoma drugs Adcetris and Opdivo in relapsed or refractory classical Hodgkin lymphoma, at the International Conference on Malignant Lymphoma in Switzerland. The drugs have not been approved, in combination, for the condition or for other indications.

$SGMO {{ '2017-05-11T12:04:01+0000' | timeago}} • Announcement

$SGMO said it is eligible to receive potential milestone payments of up to $475MM, including up to $300MM for the development and commercialization of SB-525 and up to $175MM for additional Hemophilia A gene therapy product candidates that may be developed under the collaboration with $PFE.

$SGMO {{ '2017-05-11T12:03:12+0000' | timeago}} • Announcement

$SGMO said it will be responsible for conducting the SB-525 Phase 1/2 clinical study and certain manufacturing activities. $PFE will be operationally and financially responsible for subsequent research, development, manufacturing and commercialization activities for SB-525 and additional products, if any.

$SGMO {{ '2017-05-11T12:02:25+0000' | timeago}} • Announcement

$SGMO and $PFE announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of $SGMO's four lead product candidates, which $SGMO expects will enter the clinic this quarter. $SGMO will receive a $70MM upfront payment from $PFE.

$AMAG {{ '2017-01-10T13:22:36+0000' | timeago}} • Announcement

$AMAG and $PTN entered into an agreement for exclusive North American rights to develop and commercialize Rekynda. $AMAG will also pay $PTN tiered royalties on net sales ranging from high single-digit to low double-digit percentages. $AMAG expects the transaction to close in 1Q17.

$AMAG {{ '2017-01-10T13:21:11+0000' | timeago}} • Announcement

$AMAG said the expected filing date in the U.S. for a new drug application for Rekynda is in early 2018, with expected approval and launch by early 2019. $AMAG will pay to $PTN $60MM of upfront consideration, up to $80MM contingent upon achieving certain regulatory milestones and up to $300MM contingent upon meeting certain sales milestones.

$AMAG {{ '2017-01-10T13:18:43+0000' | timeago}} • Announcement

$AMAG and $PTN entered into an agreement for exclusive North American rights to develop and commercialize Rekynda (bremelanotide), an investigational product designed for on-demand treatment of hypoactive sexual desire disorder in pre-menopausal women, that has successfully completed two Phase 3 trials.

$RGEN {{ '2016-12-15T12:52:20+0000' | timeago}} • Announcement

$RGEN acquired TangenX Technology Corporation through an all cash transaction of $39MM. $RGEN expects sales of TangenX products to achieve double-digit growth and contribute $7-7.5MM in revenue for 2017. This acquisition is expected to be accretive on both a GAAP EPS and adjusted EPS basis in 2017.

$TECH {{ '2016-10-31T14:59:36+0000' | timeago}} • Webcast

In FY17, $TECH expects overall organic growth to be similar, if not slightly ahead of FY16. The company expects 2Q17 Diagnostics revenue to be relatively flat to the prior year. Adjusted operating margin is expected to improve in 2H17, as Advanced Cell Diagnostics' revenue continues to ramp, producing more volume leverage for the Biotech segment.

$TECH {{ '2016-10-31T14:51:07+0000' | timeago}} • Webcast

$TECH ended 1Q17 with $122MM of cash and short-term available-for-sale investments. The company's long-term debt obligations at the end of 1Q17 stood at $375.9MM, an increase of $245.9MM from the end of 4Q16.

$TECH {{ '2016-10-31T14:47:56+0000' | timeago}} • Webcast

$TECH had $26.1MM of cash from operations in 1Q17, and its investment in CapEx was $2.4MM. The new ERP system that was implemented in July 2016 delayed some customer invoicing until later in the quarter, driving 1Q17-end accounts receivable balance approx. $10MM higher. $TECH expects these outstanding receivables to be fully collected in 2Q17.

$TECH {{ '2016-10-31T14:44:24+0000' | timeago}} • Webcast

$TECH paid out dividends of $11.9MM in 1Q17. Average diluted shares were up less than 1% over the year-ago period at 37.5MM shares outstanding.

$TECH {{ '2016-10-31T12:53:08+0000' | timeago}} • Announcement

$TECH's Biotechnology segment had net sales of $86.8MM in 1Q17, an increase of 15% from $75.7MM last year. Diagnostics segment's 1Q17 net sales were $24.2MM, an increase of 19% from a year ago. Protein Platforms segment revenue was $19.6MM, an increase of 20% from $16.3MM last year.

$TECH {{ '2016-10-31T12:50:42+0000' | timeago}} • Announcement

$TECH posted a decrease in 1Q17 earnings, hurt by acquisition-related amortization and other acquisition-related costs, compared to 1Q16. Net earnings were $16.3MM or $0.43 per share compared to $22.7MM or $0.61 per share last year. Net sales rose 16% from last year to $130.6MM. Adjusted EPS grew to $0.84 per diluted share, versus $0.79 last year.

$QGEN {{ '2016-09-12T09:17:25+0000' | timeago}} • Announcement

$QGEN said no meaningful revenue contribution from GeneReader NGS System were included in its 2016 financial forecasts. Company also does not expect a material impact from the court's decision on its full-year 2016 outlook nor anticipates any material changes to its internal 2017 projections. A trial date in the case is scheduled for Nov. 2017.

$QGEN {{ '2016-09-12T09:17:12+0000' | timeago}} • Announcement

Assay technologies provider $QGEN said it disagrees with the US District Court for the Northern District of California, San Francisco Division's decision, in which the Court granted the motion for a preliminary injunction against the company as part of a litigation filed by a competitor alleging patent infringement by $QGEN's GeneReader NGS System.

$TECH {{ '2016-08-17T15:23:55+0000' | timeago}} • Webcast

Amanda Murphy of William Blair asks for an update on $TECH's operating margins. CEO Chuck Kummeth replied that with the dilution this coming year with ACD and Zephyrus and what it is doing, the company believes mid-30s is a safe number. He added that the company will be clawing back to the 40% number by working on productivity and synergies.

$TECH {{ '2016-08-17T15:08:43+0000' | timeago}} • Webcast

$TECH said that $36.3MM of cash was generated from operations in 4Q16 and its investment in CapEx was $3MM. The company ended 4Q16 with $95.8MM of cash and short-term available for sale investments, and long-term debt obligations at 4Q16-end stood at $126.5MM, a decrease of $31.3MM from the end of 3Q16.

$TECH {{ '2016-08-17T15:05:43+0000' | timeago}} • Webcast

$TECH stated that its other non-operating expense for 4Q16 was $1.9MM compared to $0.9MM of non-operating income in 4Q15. Adjusted effective tax rate in 4Q16 was 31.6%, an increase of 40 BPs from last year due to a greater percentage of taxable income being generated in the US, driven in part by the Cliniqa acquisition.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
SGMO (Sangamo Biosciences Inc.)
Wednesday, May 10 2017 - 9:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
RGEN (Repligen Corporation)
Thursday, May 4 2017 - 12:30pm
QGEN (Qiagen NV)
Wednesday, May 3 2017 - 1:00pm
TECH (Bio-Techne Corp.)
Tuesday, May 2 2017 - 1:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, April 27 2017 - 8:30pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, February 28 2017 - 10:00pm
SGMO (Sangamo Biosciences Inc.)
Tuesday, February 28 2017 - 1:30pm
RGEN (Repligen Corporation)
Wednesday, February 22 2017 - 1:30pm
ONVO (Organovo Holdings, Inc.)
Thursday, February 9 2017 - 10:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, February 9 2017 - 9:30pm
PTN (Palatin Technologies Inc.)
Thursday, February 9 2017 - 4:00pm
TECH (Bio-Techne Corp.)
Tuesday, February 7 2017 - 2:00pm
QGEN (Qiagen NV)
Thursday, February 2 2017 - 2:00pm
RGEN (Repligen Corporation)
Thursday, November 3 2016 - 12:30pm
QGEN (Qiagen NV)
Wednesday, November 2 2016 - 9:00pm

AlphaGraphics you may like